SCHEMBL1747402

SCHEMBL1747402

COC(=O)CCc1ccc(OCc2ccc(CN(c3nc(-c4ccccc4)cs3)C(C)C)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 3/20 0.48
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
NPSR1 Q6W5P4 2/20 0.47
MAPT P10636 3/20 0.46
PTPRB P23467 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
GSTO1 P78417 1/20 0.44
HTT P42858 1/20 0.44
PTPRF P10586 1/20 0.42
PTPN2 P17706 1/20 0.42
PTPN1 P18031 1/20 0.42
PTPN11 Q06124 1/20 0.42
ALDH1A1 P00352 1/20 0.42
PPARD Q03181 2/20 0.42
VDR P11473 1/20 0.42
FFAR4 Q5NUL3 1/20 0.41
APP P05067 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1633626 0.92 FFAR1 (0.56) FFAR1KMT2AMEN1NPSR1MAPT
SCHEMBL1746563 0.88 KMT2A (0.49) FFAR1KMT2AMEN1NPSR1MAPT
SCHEMBL3917024 0.87 NPSR1 (0.53) FFAR1KMT2AMEN1NPSR1MAPT
SCHEMBL1745444 0.87 KMT2A (0.48) FFAR1KMT2AMEN1NPSR1MAPT
SCHEMBL1744677 0.86 FFAR1 (0.47) FFAR1KMT2AMEN1NPSR1MAPT
SCHEMBL1745481 0.85 NPSR1 (0.47) FFAR1KMT2AMEN1NPSR1MAPT
SCHEMBL3912639 0.83 PPARD (0.44) FFAR1KMT2AMEN1NPSR1MAPT
SCHEMBL1745362 0.82 NPSR1 (0.48) FFAR1KMT2AMEN1NPSR1MAPT
SCHEMBL1745386 0.82 ATP4A (0.45) FFAR1KMT2AMEN1NPSR1MAPT
SCHEMBL3913216 0.82 FFAR1 (0.57) FFAR1KMT2AMEN1NPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR FFAR1 33/4885KMT2A 4408/4885MEN1 2579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.